Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 5;35(11):1123–1140. doi: 10.1007/s40273-017-0540-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

PMC Copyright notice

Fig. 1 — Number and percentage of EEs reporting positive and negative cost-effectiveness results for each treatment for CDI. CDI Clostridium difficile infection, EE economic evaluation, FDX fidaxomicin, FMT faecal microbiota transplant, MTZ metronidazole, VNC vancomycin. ^aNumber of EEs is >27, as two EEs reported >1 treatment to be cost-effective [65]. ^bNote that cost-effectiveness thresholds vary according to EE and region. ^cFMT was evaluated in six EEs only, but there were multiple comparisons with other treatments in some EEs (also note that FMT was not included as a search term in the systematic literature review). ^dEE compared FDX with ‘no FDX’ strategy (VNC or MTZ) [37]. One EE was not included in the figure as the cost-effectiveness conclusion was unclear from the publication [29]